Recentin (cediranib) / AstraZeneca - LARVOL DELTA

WIRE - Novel Treatments in Renal Cell Cancer (clinicaltrials.gov) - P2 | N=134 | Recruiting | Sponsor: CCTU- Cancer Theme | N=60 ➔ 134 | Trial completion date: Nov 2025 ➔ Dec 2027 | Trial primary completion date: Nov 2025 ➔ Dec 2027

Enrollment change • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IL2 • TIGIT

NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer (ESMO 2025) - P2 | "Methods Eligible patients (pts) had at least 1 prior line of chemotherapy (no more than 2) with prior endocrine and immunotherapy (prior lenvatinib/pembrolizumab excluded) allowed, ECOG 0-1. Conclusions The combinations of O+D, O+CA and C+D did not meet prespecified endpoints for significance in an unselected population. Further evaluation of molecular subgroups and prior immunotherapy treatment is necessary to determine if there are any signals warranting future investigation."

Clinical • Metastases • P2 data • Endometrial Cancer • Oncology • Solid Tumor

WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer (KCRS 2024) - P2 | "Cediranib + Olaparib (a PARP inhibitor), 3...Volrustomig (anti PD-1/CTLA4 bispecific) and 5. Rilvegostomig (anti PD-1/TIGIT bispecific)...WIRE may identify novel biomarkers of response and toxicity, to inform treatment selection for patients. The data generated will be a foundation for further trials of these IMPs in advanced disease."

Clinical • IO biomarker • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • TIGIT

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. (PubMed, J Clin Oncol) - "Cediranib combined with olaparib improved rPFS compared with olaparib alone in men with mCRPC. This combination was associated with an increased incidence of grades 3-4 adverse events. BRCA2-mutated subgroups treated with olaparib with or without cediranib were associated with a numerically longer median rPFS."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA2 • HRD

Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial. (PubMed, Clin Cancer Res) - "A second course of olaparib can be safely administered to women with gBRCAm-HGSOC but is only modestly efficacious."

Journal • P2 data • Acute Myelogenous Leukemia • Fatigue • Hematological Disorders • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • BRCA1 • BRCA2 • HRD

Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial. (PubMed, Clin Cancer Res) - "In PROC patients with prior bevacizumab, all experimental arms failed to reach the primary objective of improving PFS compared with SOC."

Journal • Monotherapy • P2 data • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005. (PubMed, J Clin Oncol) - "The cediranib-containing arms demonstrated clinical activity on the basis of PFS but were not superior compared with SOC."

Journal • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

Randomized Phase 2 Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. (PubMed, Clin Cancer Res) - "The study did not meet its endpoints for ORR. Although both TKIs provided clinical benefit, the outcomes may have been attenuated in patients who had progressed ≤6 months before enrollment, potentially accounting for the low response rates."

Journal • P2 data • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy (ESMO 2024) - P3 | "Stratification was by country, tumour BRCA (tBRCA), prior bevacizumab, platinum-free interval, surgery at relapse. Maintenance O+C did not improve efficacy compared to O. PARPi alone led to better than anticipated outcomes. Translational work to identify patients who might benefit most from this approach is ongoing."

Clinical • Late-breaking abstract • P3 data • Gynecologic Cancers • Oncology • Ovarian Cancer • BRCA

ICON9: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients. (ANZCTR) - P3 | N=118 | Completed | Sponsor: The University of Sydney | Active, not recruiting ➔ Completed

Trial completion • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • MUC16

Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS). (ASCO 2026) - P3 | " Adult patients with pathologic and molecularly confirmed advanced ASPS, either treatment-naive or previously treated (excluding cediranib), were enrolled in the open-label, non-randomized ASPS cohort of the phase III APROMISS trial conducted across the United States, Asia, and Europe. Catequentinib hydrochloride demonstrated meaningful antitumor activity and durable responses in adults with advanced ASPS. Despite the ORR of 26.8% slightly below the predefined 31% threshold, disease control was prolonged, with a m-DOR exceeding 22 months. Favorable PFS and OS outcomes, together with a manageable safety profile, support its clinical benefit in this ultra-rare sarcoma."

Clinical • Metastases • Monotherapy • P3 data • Alveolar Soft Tissue Sarcoma • Cardiovascular • Hypertension • Respiratory Diseases • Sarcoma • Solid Tumor

NRG-GY012: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (clinicaltrials.gov) - P2 | N=288 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2027 ➔ Jul 2027

Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer

Biophysical insights into interaction mechanism of cediranib with human serum albumin: In-vitro and in-silico perspectives. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "The preferred binding pose of CB was positioned at Sudlow's site I of HSA, and the CB-HSA complex bound at site I persisted compact and stable through hydrogen bonds and hydrophobic interactions during molecular dynamics simulations. These findings offer important insights into the binding properties of CB to HSA that might be useful for pharmaceutical applications in the future."

Journal • Preclinical • Brain Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and Safety of Olaparib Combined With Cediranib in the Treatment of Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Technol Cancer Res Treat) - "No significant benefit was observed in overall survival (OS) or overall objective response rate (ORR), demonstrated improved ORR compared with olaparib or cediranib monotherapy, but not compared with chemotherapy or olaparib plus durvalumab. Evidence certainty ranged from very-low to moderate.ConclusionOlaparib plus cediranib may prolong PFS in OC, and the benefit may limit in BRCA-mutated populations, but no clear OS benefit was observed and toxicity was increased. Because trials were judged to be at high risk of bias and the certainty of evidence ranged from very-low to moderate, these findings should be interpreted cautiously and considered hypothesis-generating."

Clinical • Journal • Retrospective data • Review • Fatigue • Gynecologic Cancers • Hematological Disorders • Oncology • Ovarian Cancer • Solid Tumor • BRCA

A prognostic signature based on methionine metabolism-related genes for cervical cancer: integrated transcriptomic and experimental validation. (PubMed, PeerJ) - "Notably, agents such as Cediranib and BI-2536 exhibited markedly lower IC50 values in the high-risk cohort, suggesting their potential efficacy for advanced-stage treatment. qRT-PCR preliminarily indicated the overexpression of four genes in CC tissues within a small clinical cohort. This study establishes a novel MM-based prognostic model for CC and based on in-silico predictions suggests potential therapeutic targets through comprehensive transcriptomic and experimental validation."

Biomarker • Journal • Cervical Cancer • Oncology • Solid Tumor • DNMT3B • SMYD2

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2027 ➔ Jun 2027

Platinum resistant • Trial completion date • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • Urothelial Cancer • BRCA1 • BRCA2 • PD-L1

LD-associated signatures identified by perilipin-based proximity labeling proteomics reveal GNA14 as a therapeutic and prognostic target in renal cell carcinoma. (PubMed, Cancer Gene Ther) - "Drug sensitivity analysis suggested differential responses to Sorafenib, Cediranib, and Saracatinib...Excitingly, lovastatin can partially block the detrimental pathway by which GNA14 promotes lipid accumulation. Therefore, combining lovastatin with GNA14 overexpression yields a more effective suppression of RCC."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Metabolic Disorders • Oncology • Renal Cell Carcinoma • Solid Tumor • PLIN2

A Tale of Two Cell Lines: Characterization of Differential Efficacy of Small Molecule Drugs Cediranib and NU-7441 on Primary Versus Metastatic Colorectal Cancer. (PubMed, Pharmacol Res Perspect) - "An SW620 line grown in non-attachment plates and then reattached (SW620F) exhibited high DNA-PKcs activation and drug sensitivity. Correlation between drug response and gene expression crucial to cell growth and successful metastasis may reveal new biomarkers to target potential treatments."

Journal • Preclinical • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • PROM1 • TGM2

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. (PubMed, EClinicalMedicine) - P2 | "Further evaluation of paclitaxel plus cediranib in patients previously treated with platinum-based chemotherapy and immunotherapy is warranted, ideally incorporating plasma Tie2 as a response biomarker to guide treatment continuation. AstraZeneca."

IO biomarker • Journal • P2 data • Cardiovascular • Endometrial Cancer • Hematological Disorders • Hypertension • Neutropenia • Oncology • Solid Tumor

CLIP2 is a potential biomarker for platinum resistance and prognosis in ovarian cancer: a bioinformatics analysis. (PubMed, Transl Cancer Res) - "Drug sensitivity analysis revealed that high CLIP2 expression conferred resistance to platinum-based agents, topotecan, and gemcitabine, but heightened sensitivity to olaparib, cediranib, and pictilisib. Through bioinformatic analysis, this study proposes CLIP2 as a potential biomarker associated with platinum resistance and immune microenvironment patterns in ovarian cancer. These preliminary findings provide a basis for subsequent mechanistic studies and larger validation cohorts to confirm its clinical relevance in guiding immunotherapy and targeted treatment approaches."

Biomarker • IO biomarker • Journal • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • ADORA2A • CD276 • CD48 • CD8 • ENTPD1

Identification of checkpoint inhibitor resistance mechanisms in leiomyosarcoma through enrichment of active chromatin-associated cell-free DNA. (ASCO 2026) - P2 | "We previously showed (Lopes, ASCO 2025) that a liquid biopsy assay enriching for active chromatin–associated cell-free DNA (cfDNAac) identified biomarkers predicting clinical benefit in LMS pts treated with durvalumab plus olaparib or cediranib (NCT03851614). This active chromatin-associated cell-free DNA profiling enables a non-invasive monitoring of dynamic tumor microenvironment remodeling over time and provides insights into emerging mechanisms of resistance to CPI in LMS pts."

cfDNA • Checkpoint inhibition • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ May 2027

Trial completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Neuroendocrine Carcinoma • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004. (PubMed, Gynecol Pelvic Med) - No abstract available

Journal • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

Blood proteomics of paediatric bronchiolitis obliterans syndrome after haematopoietic cell transplant. (PubMed, ERJ Open Res) - "Pathways analysis highlighted potential therapeutics including azithromycin, statins, pazopanib and cediranib. Our strategy offers a potential for early diagnosis and the identification of interventions for paediatric stem cell transplant-associated graft-versus-host disease and BOS."

Journal • Fibrosis • Graft versus Host Disease • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases • Transplantation